How patients navigate quality-of-life challenges associated with geographic atrophy
Investigators sought to understand the diagnostic path, symptoms, quality of life impact and coping mechanisms of patients with GA in western Europe and the United States
AAVantgarde Bio presents positive data for retinitis pigmentosa and Stargardt disease therapies
The company shared results from the AAVB-081 clinical programme and AAVB-039 preclinical programme at ARVO
EyeCool Therapeutics announces results from pilot study of novel chronic ocular surface pain treatment
The investigational device, ETX-4143, was the focus of a study involving 31 patients with COSP in Australia
Retinal microvascular changes in patients with systemic lupus erythematosus: Importance of OCTA
The biomarkers are especially crucial for patients with lupus nephritis
Topcon Healthcare, Inc. appoints Krysten Williams Head of Digital Solutions & Clinical Development – EMEA
Williams joins Topcon Healthcare from Heidelberg Engineering, where she held multiple senior leadership roles.
Teprotumumab (Tepezza, Amgen) receives marketing authorisation from MHRA
Teprotumumab is the first therapy specifically licensed for the treatment of moderate-to-severe thyroid eye disease in the UK
ARVO 2025: Alfredo Sadun, MD, PhD, says "later is better" for some LHON interventions
At the 2025 ARVO annual meeting, Prof Sadun shared an exciting update in our understanding of Leber hereditary optic neuropathy
Moorfields, Topcon, IoO announce partnership launch of Cascader
Utilizing artificial intelligence (AI), Cascader is a new medical technology company that aims to transform the detection and management of eye disease.
ARVO 2025: Nitish Mehta, MD, provides real-world insights from aflibercept 8 mg for treatment-naive diabetic macular oedema
ARVO 2025: Anat Loewenstein, MD, and colleagues on meeting needs of patients with diabetic retinopathy
Prof Loewenstein and a cohort of colleagues assessed the current treatment outlook for patients with diabetic retinopathy
Editorial Advisory Board members bring research findings to ARVO
Members of the Ophthalmology Times Europe, Ophthalmology Times and Modern Retina editorial advisory boards are present and presenting at the 2025 ARVO meeting
ZEISS debuts Research Data Platform, highlights Boehringer Ingelheim partnership
Carl Zeiss Meditec plans to launch the ZEISS RDP in select countries throughout 2025
LuxIA receives CE-MDR certification
LuxIA is designed to screen adult diabetic patients for more-than-mild diabetic retinopathy.
EMA CHMP adopts positive opinion for teprotumumab (Tepezza, Amgen) marketing authorisation application
In the weeks to come, the European Commission will issue a decision on the first severe thyroid eye disease treatment
The future of microbial keratitis treatment is bright
Ultraviolet light’s potential in ocular care extends beyond structural reinforcement to antimicrobial applications, especially for microbial keratitis
Sheng Lim, MD, FRCOphth, brings data from the CONCEPT study to the ASCRS meeting
Endoscopic cyclophotocoagulation (ECP) has major potential for patients with glaucoma
Vision- and life-threatening neuro-ophthalmological presentations
Paediatric diagnoses of juvenile idiopathic intracranial hypertension, optic neuritis and Horner syndrome
Diagnosing types of dry eye in patients with autoimmune disease
ENTOD Pharmaceuticals announces CDSCO approval of 0.05% atropine drops (Myatro XL)
According to a press release, Myatro XL is the first 0.05% atropine eye drop for paediatric myopia control.
Investigating causes of diplopia to minimise morbidity and mortality
Canadian investigators urged quick neuro-ophthalmologic referrals to limit the progress of life- and vision-threatening conditions
Neurotech appoints Beth Marsh as chief commercial officer ahead of US product launch
The US FDA recently approved revakinagene taroretcel-lwey (ENCELTO) for the treatment of idiopathic macular telangiectasia type 2 (MacTel)
New trends in the diagnosis of dry eye disease: A patient-centric approach
A five-step approach to personalise and simplify treatment, leading to higher efficacy
Regeneron announces US FDA complete response letter for aflibercept 8 mg (Eylea HD) supplemental Biologics License Application
The US Food and Drug Administration did not identify any safety or efficacy issues associated with aflibercept 8 mg
Industry updates and clinical trial data at the upcoming 2025 ARVO Annual Meeting
Therapies for retinal vascular disease, dry eye disease, inflammation following glaucoma filtration surgery and more
DMO study meta-analysis illuminates how racial subgroups are underrepresented in clinical trials
The study aimed to clarify how race affects visual outcomes for patients with diabetic macular oedema treated with ranibizumab
Artificial intelligence analyses biomarker changes in neovascular AMD treated with faricimab
The phase 3 LUCERNE and TENAYA trials suggested that faricimab may allow clinicians to extend the interval between injections to up to 16 weeks after an initial loading phase
Clinicians may improve follow-up adherence by leveraging social media apps
Social media smartphone application–based interventions significantly improved adherence and parental knowledge among families of children with congenital ectopia lentis
Journal of Neuroinflammation publishes data on Eleva’s lead retinal asset CPV-104
In an established animal model of age-related macular degeneration, Eleva’s recombinant human CPV-104 improved two hallmarks of the disease
Alcon marks 110th anniversary of Grieshaber AG site in Switzerland
Alcon acquired the historic ophthalmic instrument company in 2000
Eyestem Research announces positive results from phase 1 geographic atrophy trial
Bangalore-based Eyestem will share more research findings on Eyecyte-RPE at this year's Association for Research in Vision and Ophthalmology meeting
